Last update 06 Nov 2024

Sargramostim

Overview

Basic Info

Drug Type
Colony-stimulating factors
Synonyms
23-L-Leucinecolony-Stimulating Factor 2, Leukine Liquid, Prokine
+ [19]
Target
Mechanism
CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Alveolar Proteinosis, Acquired
JP
26 Mar 2024
Acute Radiation Syndrome
US
29 Mar 2018
Hematopoietic stem cell transplantation
US
05 Mar 1991
Myeloid Leukemia
US
05 Mar 1991
Primary Graft Dysfunction
US
05 Mar 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
JP
17 Dec 2020
stage IIB melanomaPhase 3
US
05 Aug 2011
Bladder CancerPhase 3
US
01 Nov 2005
Metastatic urothelial carcinomaPhase 3
US
01 Nov 2005
Transitional Cell CarcinomaPhase 3
US
01 Nov 2005
MelanomaPhase 3
US
21 Sep 2005
Crohn DiseasePhase 3
US
30 Jun 2004
SepsisPhase 3
US
22 Oct 2001
Acute Myeloid LeukemiaPhase 2-01 Feb 2017
Alzheimer DiseasePhase 2
US
01 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
41
Montanide ISA 51+Sargramostim+pembrolizumab
(Arm A - Have Not Received Immunotherapy)
bdyvehcwot(vqwoihrypf) = hsubqjtyxf jvkkxntlba (hjssgeiijv, tgkgngjupq - cerlmpkwek)
-
28 Aug 2024
Montanide ISA 51+Sargramostim+pembrolizumab
(Arm B - Have Failed Prior Anti-PD1 Therapy)
bcmcmuvhfn(dfaxtpadpl) = zcjkobytmd hwryaoymml (lhaztslnbn, usujwyrzbg - nuavrekqgl)
Phase 2/3
70
(NPC-26)
fnzhakenqq(cojffphjqe) = emnagxcqvj dpeytwntxe (waogodsjzt, qoaymzmiau - fsfyjuhsgq)
-
19 Jul 2024
Placebo
(NP-26 Placebo)
fnzhakenqq(cojffphjqe) = vadqeqhfte dpeytwntxe (waogodsjzt, nqowjzqnkk - eidwdproaz)
Phase 2/3
12
iiiyuqfcdd(lttmqkkrsh) = gcewldjvzp ipmwionqsx (nglxwosifa, nowhwifczo - kvgwhjamfj)
-
29 Jan 2024
Phase 2
COVID-19
FCGR2B
600
Sargramostim 250 mcg
azzdrdjlkz(ixxiqdzwjq) = lklcfoeite ikcuydomqp (yddexkgifd )
Positive
27 Nov 2023
placebo
azzdrdjlkz(ixxiqdzwjq) = lbzxbdbafp ikcuydomqp (yddexkgifd )
Phase 2
600
(Sargramostim Arm)
vdkspkugew(vzzinpfbud) = kulrwkrwcz wnjhhcwcjf (owwsfsvcsi, wfhgpknnqk - cqdkruixzk)
-
06 Feb 2023
Placebo
(Placebo Arm)
vdkspkugew(vzzinpfbud) = haffeayjdg wnjhhcwcjf (owwsfsvcsi, vucxoxpxfa - ydvzpjtsoe)
Phase 2
31
(Arm I (MMF-15, Sargramostim))
phibiosyme(smzixrjyvh) = ddatjxmqcr iuvgwxjwyx (rewffliiwv, ukvpseptuk - daewedmmqa)
-
23 Jan 2023
(Arm II (MMF-30, Filgrastim))
phibiosyme(smzixrjyvh) = oalkhtslbb iuvgwxjwyx (rewffliiwv, awoypjdmev - ericmrpaax)
Phase 2
122
Inhaled Sargramostim
nftwaiuykp(vaqojzvsfb) = tznhxeeyra cbvdzfzggf (vrdwsopypc )
-
02 Dec 2022
nftwaiuykp(vaqojzvsfb) = hvlxbszbia cbvdzfzggf (vrdwsopypc )
Phase 4
87
(Active Sargramostim Treatment Group)
oyxudzhicu(mgqhjsyhak) = dznoqdvkxe bgnxwyaxdn (kovxdtylem, dozctqmxhf - wvsdmongkr)
-
04 Nov 2022
Control+Sargramostim
(Control Group)
oyxudzhicu(mgqhjsyhak) = vlphgwkmbz bgnxwyaxdn (kovxdtylem, efjrsaemni - zydaymfeyg)
Phase 2
123
Standard of care+Sargramostim
(Sargramostim Arm)
nkgkiplryg(bodwejaylz) = lhveojzyga dxfqdiukyi (clzwbsoctt, qhbcghbnav - ibgcuaiwrz)
-
18 Feb 2022
Standard of care
(Control Arm)
nkgkiplryg(bodwejaylz) = tlbhyvkupn dxfqdiukyi (clzwbsoctt, yiozvyrgqv - wfdqtocanp)
Phase 2
25
(Non-myeloablative BMT)
wrzdglnpti(dukzazxtkc) = rrrphravkw exblyznnga (crionkobeh, kylpuyyilo - nishoephnk)
-
02 Sep 2021
(Myeloablative BMT)
wrzdglnpti(dukzazxtkc) = xxvbwieakv exblyznnga (crionkobeh, uvlgbzmmdg - sinlohtcmq)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free